In vivo activity of an azole series of CCR2 antagonists-Reference-Cited by-同舟云学术

In vivo activity of an azole series of CCR2 antagonists

Published:2012-12 Issue:23 Volume:22 Page:7252-7255
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Smethurst Chris A.,Bevan Nicola,Brooks Carl,Emmons Amanda,Gough Peter J.,Mookherjee Claudette,Moores Kitty,Peace Simon,Philp Joanne,Piercy Val,Watson Steve P.,Zippoli Mara

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference14 articles.

1. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis

2. Drug targets in inflammation and immunomodulation

3. Chemokines and atherosclerosis

4. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice

5. Selective lymphocyte chemokine receptor expression in the rheumatoid joint

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5;2023-11-17

2. Compounds Containing Azole Scaffolds as Cyclooxygenase Inhibitors: A Review;Current Topics in Medicinal Chemistry;2016-10-21

3. Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview;Topics in Medicinal Chemistry;2014

4. Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 – 2012;Expert Opinion on Therapeutic Patents;2013-02-22

5. Corrigendum to “In vivo activity of an azole series of CCR2 antagonists” [Bioorg. Med. Chem. Lett. 22 (2012) 7252–7255];Bioorganic & Medicinal Chemistry Letters;2013-01